Literatur – 1. Neu – aber auch besser?

1. Vandenbroucke JP. Thalidomide: an unanticipated adverse event. 2003. Zugänglich unter:

2. Stephens T, Brynner R. Dark medicine: the impact of thalidomide and its revival as a vital medicine. Cambridge, Mass: Perseus Publishing, 2001.

3. Thomson D, Capstick T. How a risk management programme can ensure safety in thalidomide use. Pharmaceutical Journal 2004 Feb 14: 194–195.

4. Krumholz HM, Ross JR, Presler AH, et al. What have we learnt from Vioxx? BMJ 2007; 334: 120–123.

5. Erklärungen der Fa. Merck vom 7. Dezember 2009 zum Vioxx-Gerichtsverfahren um in Ontario, Kanada, sowie vom 4. März 2010 zum Vioxx-Urteil in Australien, zugänglich unter

6. Cohen D. Rosiglitazone what went wrong? BMJ 2010; 341: c4848.

7. Lehman R, Yudkin JS, Krumholz HM. Licensing drugs for diabetes: surrogate end points are not enough, robust evidence of benefits and harms is needed. BMJ 2010; 341: c4805.

8. Blackstone EH. Could it happen again? The Björk-Shiley convexo-concave heart valve story. Circulation 2005; 111: 2717–2719.

9. Wilson PM, Booth AM, Eastwood A, et al. Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage. Journal of the Royal Society of Medicine 2008; 101: 125–132.

10. Timmins N. Drugs watchdog gets harsh treatment. Financial Times, 8. Oktober 2005, S. 6.

11. Hawkes N. Wonder drug is «cure» for cancer, say doctors. The Times, 20. Oktober 2005.

12. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clinical Cancer Research 2005; 11(18): 6598–6607.

13. NICE draft guidance on trastuzumab (Herceptin) for early breast cancer (Pressemitteilung), 9. Juni 2006.

14. Cumming J, Mays N, Daubé J. How New Zealand has contained expenditure on drugs. BMJ 2010; 340: 1224–1226.

15. NHS NICE Technology Appraisal TA34. Guidance on the use of trastuzumab for the treatment of advanced breast cancer. Erscheinungsdatum März 2002; Revisionsdatum April 2005.